Table 3 |
||
|
Adverse events occurring in at least 10% of patients in either treatment group. |
||
|
Adverse event |
Sugammadex (n = 46) |
Neostigmine (n = 36) |
|
|
||
|
Procedural pain |
33 (71.7) |
24 (66.7) |
|
Nausea |
24 (52.2) |
12 (33.3) |
|
Incision-site complication |
10 (21.7) |
8 (22.2) |
|
Pharyngolaryngeal pain |
8 (17.4) |
7 (19.4) |
|
Headache |
12 (26.1) |
2 (5.6) |
|
Vomiting |
9 (19.6) |
4 (11.1) |
|
Dizziness |
5 (10.9) |
4 (11.1) |
|
Pruritus |
5 (10.9) |
2 (5.6) |
|
Post-procedural nausea |
5 (10.9) |
2 (5.6) |
|
Constipation |
5 (10.9) |
0 |
|
Chills |
5 (10.9) |
0 |
|
|
||
|
Adverse events are listed regardless of their perceived relationship to study drug for the all-subjects-treated population (n = 82). |
||
|
Lemmens et al. BMC Anesthesiology 2010 10:15 doi:10.1186/1471-2253-10-15 |
||
